Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant and Palonosetron for CINV in Colorectal Cancer
NCT00381862Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of aprepitant and palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by OHSU Knight Cancer Institute. Started Jun 2006; status: completed.
02
Drugs
aprepitantpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00381862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381862.